Unlike GLP-1s, PCSK9 inhibitors are a near "free lunch." Discovered from a genetic mutation in a population with virtually no heart disease, these drugs dramatically lower bad cholesterol with minimal trade-offs, making them an ideal preventative tool.

The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

The massive success of GLP-1s is not just about a $100B drug class. It's the first commercial proof that consumers are actively choosing preventative medicine, paving the way for a broader, trillion-dollar revolution in public health spending and behavior.

A $2,000 preventative injection like a PCSK9 inhibitor sounds expensive. However, its cost is likely justified when calculated against the massive societal and individual expense of future medical bills, plus the economic value of additional healthy, productive years.

Contrary to Wall Street's focus on ever-increasing efficacy, real-world data shows GLP-1 users optimize for tolerability. They prefer a sustainable dose that offers health benefits without severe side effects, maximizing their ability to stay on the drug long-term.

A major challenge in managing high cholesterol is patient adherence to daily medication for life. New therapies like Inclisiran use mRNA silencing and require only two injections per year, dramatically improving adherence for busy or non-compliant individuals.

The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

The silent nature of high cholesterol creates a psychological barrier. Patients who feel perfectly healthy are often unwilling to commit to lifelong treatment, even when their risk is high, leading to preventable cardiovascular events.